Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells

REFERENCES

• Bergelson, J.M.; Cunningham, J.A.; Droguett, G.; Kurt-Jones, E.A.; Krithivas, A.; Hong, J.S.; Horwitz, M.S.; Crowell, R.L.; Finberg, R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275, 1320–1323.
   PubMed Web of Science ®Google Scholar
• Cohen, C.J.; Shieh, J.T.; Pickles, R.J.; Okegawa, T.; Hsieh, J.T.; Bergelson, J.M. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001, 98, 15191–15196.
   PubMed Web of Science ®Google Scholar
• Raschperger, E.; Thyberg, J.; Pettersson, S.; Philipson, L.; Fuxe, J.; Pettersson, R.F. The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. Exp Cell Res 2006, 312, 1566–1580.
   Google Scholar
• Bruning, A.; Runnebaum, I.B. CAR is a cell--cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 2003, 10, 198–205.
   PubMed Web of Science ®Google Scholar
• Bruning, A.; Runnebaum, I.B. The coxsackie adenovirus receptor inhibits cancer cell migration. Exp Cell Res 2004, 298, 624–631.
   PubMed Web of Science ®Google Scholar
• Huang, K.C.; Altinoz, M.; Wosik, K.; Larochelle, N.; Koty, Z.; Zhu, L.; Holland, P.C.; Nalbantoglu, J. Impact of the coxsackie and adenovirus receptor (CAR) on glioma cell growth and invasion: requirement for the C-terminal domain. Int J Cancer 2005, 113, 738–745.
   PubMed Web of Science ®Google Scholar
• Okegawa, T.; Li, Y.; Pong, R.C.; Bergelson, J.M.; Zhou, J.; Hsieh, J.T. The dual impact of coxsackie and adenovirus receptorexpression on human prostate cancer gene therapy. Cancer Res 2000, 60, 5031–5036.
   PubMed Web of Science ®Google Scholar
• Okegawa, T.; Pong, R.C.; Li, Y.; Bergelson, J.M.; Sagalowsky, A.I.; Hsieh, J.T. The mechanism of the growth-inhibitory effect ofcoxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001, 61, 6592–6600.
   PubMed Web of Science ®Google Scholar
• Wang, B.; Chen, G.; Li, F.; Zhou, J.; Lu, Y.; Ma, D. Inhibitory effect of coxsackie adenovirus receptor on invasion and metastasis phenotype of ovarian cancer cell line SKOV3. J Huazhong Univ Sci Technolog Med Sci 2005, 25, 85–7, 93.
   Google Scholar
• Buscarini, M.; Quek, M.L.; Gilliam-Hegarich, S.; Kasahara, N.; Bochner, B. Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. Urol Int 2007, 78, 160–166.
   PubMed Web of Science ®Google Scholar
• Korn, W.M.; Macal, M.; Christian, C.; Lacher, M.D.; McMillan, A.; Rauen, K.A.; Warren, R.S.; Ferrell, L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther 2006, 13, 792–797.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K.; Shariat, S.F.; Ayala, G.E.; Rauen, K.A.; Lerner, S.P. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005, 66, 441–446.
   PubMed Web of Science ®Google Scholar
• Okegawa, T.; Sayne, J.R.; Nutahara, K.; Pong, R.C.; Saboorian, H.; Kabbani, W.; Higashihara, E.; Hsieh, J.T. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol 2007, 177, 1148–1156.
   PubMed Web of Science ®Google Scholar
• Rauen, K.A.; Sudilovsky, D.; Le, J.L.; Chew, K.L.; Hann, B.;Weinberg, V.; Schmitt, L.D.; McCormick, F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002, 62, 3812–3818.
   PubMed Web of Science ®Google Scholar
• Sachs, M.D.; Rauen, K.A.; Ramamurthy, M.; Dodson, J.L.; De Marzo, A.M.; Putzi, M.J.; Schoenberg, M.P.; Rodriguez, R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002, 60, 531–536.
   PubMed Web of Science ®Google Scholar
• Anders, M.; Christian, C.; McMahon, M.; McCormick, F.; Korn, W.M. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 2003, 63, 2088–2095.
   PubMed Web of Science ®Google Scholar
• Lacher, M.D.; Tiirikainen, M.I.; Saunier, E.F.; Christian, C.;Anders, M.; Oft, M.; Balmain, A.; Akhurst, R.J.; Korn, W.M. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006, 66, 1648–1657.
   PubMed Web of Science ®Google Scholar
• Pong, R.C.; Lai, Y.J.; Chen, H.; Okegawa, T.; Frenkel, E.;Sagalowsky, A.; Hsieh, J.T. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 2003, 63, 8680–8686.
   PubMed Web of Science ®Google Scholar
• El Zawahry, A.; Lu, P.; White, S.J.; Voelkel-Johnson, C. In vitroefficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-X(L). Cancer Gene Ther 2006, 13(3), 281–9.
   PubMed Web of Science ®Google Scholar
• Goldsmith, M.E.; Kitazono, M.; Fok, P.; Aikou, T.; Bates, S.; Fojo, T. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin. Cancer Res 2003, 9, 5394–5401.
   PubMed Web of Science ®Google Scholar
• Hemminki, A.; Kanerva, A.; Liu, B.; Wang, M.; Alvarez, R.D.;Siegal, G.P.; Curiel, D.T. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003, 63, 847–853.
   Google Scholar
• Kasman, L.; Lu, P.; Voelkel-Johnson, C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 2007, 14, 327–334.
   PubMed Web of Science ®Google Scholar
• Kitazono, M.; Goldsmith, M.E.; Aikou, T.; Bates, S.; Fojo, T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001, 61, 6328–6330.
   PubMed Web of Science ®Google Scholar
• Okegawa, T.; Nutahara, K.; Pong, R.C.; Higashihara, E.; Hsieh, J.T. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol 2005, 174, 747–752.
   PubMed Web of Science ®Google Scholar
• Sachs, M.D.; Ramamurthy, M.; Poel, H.H.; Wickham, T.J.;Lamfers, M.; Gerritsen, W.; Chowdhury, W.; Li, Y.; Schoenberg, M.P.; Rodriguez, R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004, 11(7), 477–486.
   PubMed Web of Science ®Google Scholar
• Taura, K.; Yamamoto, Y.; Nakajima, A.; Hata, K.; Uchinami, H.; Yonezawa, K.; Hatano, E.; Nishino, N.; Yamaoka, Y. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression. J Gene Med 2004, 6, 526–536.
   PubMed Web of Science ®Google Scholar
• Watanabe, T.; Hioki, M.; Fujiwara, T.; Nishizaki, M.; Kagawa, S.; Taki, M.; Kishimoto, H.; Endo, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006, 312, 256–265.
   PubMed Web of Science ®Google Scholar
• Goldsmith, M.E.; Aguila, A.; Steadman, K.; Martinez, A.;Steinberg, S.M.; Alley, M.C.; Waud, W.R.; Bates, S.E.; Fojo, T. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol. Cancer Ther 2007, 6, 496–505.
   PubMed Web of Science ®Google Scholar
• Velazquez, O.C.; Lederer, H.M.; Rombeau, J.L. Butyrate and the colonocyte. Implications for neoplasia. Dig Dis Sci 1996, 41, 727–739.
   PubMed Web of Science ®Google Scholar
• Bi, G.; Jiang, G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006, 3, 285–290.
   PubMed Web of Science ®Google Scholar
• Davie, J.R. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003, 133, 2485S–2493S.
   PubMed Web of Science ®Google Scholar
• Lee, J.C.; Maa, M.C.; Yu, H.S.; Wang, J.H.; Yen, C.K.; Wang, S.T.; Chen, Y.J.; Liu, Y.; Jin, Y.T.; Leu, T.H. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells. Mol Carcinog 2005, 43, 207–214.
   PubMed Web of Science ®Google Scholar
• D'Argenio, G.; Cosenza, V.; Delle, C.M.; Iovino, P.; Delle, V.N.; Lombardi, G.; Mazzacca, G. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 1996, 110, 1727–1734.
   PubMed Web of Science ®Google Scholar
• Tietz, N.W.; Burtis, C.A.; Duncan, P.; Ervin, K.; Petitclerc, C.J.; Rinker, A.D.; Shuey, D.; Zygowicz, E.R. A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem 1983, 29, 751–761.
   PubMed Web of Science ®Google Scholar
• Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• Anders, M.; Hansen, R.; Ding, R.X.; Rauen, K.A.; Bissell, M.J.; Korn, W.M. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 2003, 100, 1943–1948.
   PubMed Web of Science ®Google Scholar
• Sambuy, Y.; de, A.; I, Ranaldi, G.; Scarino, M.L.; Stammati, A.; Zucco, F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 2005, 21, 1–26.
   PubMed Web of Science ®Google Scholar
• Mariadason, J.M.; Rickard, K.L.; Barkla, D.H.; Augenlicht, L.H.; Gibson, P.R. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. J Cell Physiol 2000, 183, 347–354.
   PubMed Web of Science ®Google Scholar
• Halbleib, J.M.; Saaf, A.M.; Brown, P.O.; Nelson, W.J. Transcriptional modulation of genes encoding structural characteristics of differentiating enterocytes during development of a polarized epithelium in vitro. Mol Biol Cell 2007, 18, 4261–4278.
   Google Scholar
• Laprise, P.; Langlois, M.J.; Boucher, M.J.; Jobin, C.; Rivard, N. Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells. J Cell Physiol 2004, 199, 32–39.
   Google Scholar
• Byrd, J.C.; Marcucci, G.; Parthun, M.R.; Xiao, J.J.; Klisovic, R.B.; Moran, M.; Lin, T.S.; Liu, S.; Sklenar, A.R.; Davis, M.E.; Lucas, D.M.; Fischer, B.; Shank, R.; Tejaswi, S.L.; Binkley, P.; Wright, J.; Chan, K.K.; Grever, M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959–967.
   PubMed Web of Science ®Google Scholar